---
title: Vitamin D normalizes brain waves
nct_id: NCT07096336
phase: NA
status: RECRUITING
sponsor: Bangladesh Medical University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07096336"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07096336"
last_fetched: "2026-05-10T14:03:25.416Z"
source: "Parkinson's Pathways (curated)"
---
# Vitamin D normalizes brain waves

**Goal (in five words):** Vitamin D normalizes brain waves

**Official Title:** Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis

**Trial ID:** [NCT07096336](https://clinicaltrials.gov/study/NCT07096336)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Bangladesh Medical University
- **Target Enrollment:** 15 participants
- **Start Date:** 2025-07-15
- **Completion Date:** 2025-11
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** vitamin D3 capsule
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

The goal is to see whether correcting low vitamin D can change abnormal brain wave patterns in men with Parkinson's, which could reflect altered neuronal excitability and brain function. Participants will take an oral vitamin D3 capsule to raise serum 25(OH)D; vitamin D3 acts on neurons and calcium signaling and may reduce neuronal hyperexcitability, and researchers will measure quantitative EEG while patients stay on their usual levodopa because vitamin D3 is not expected to change how levodopa works. The study seeks men aged 51 to 70 with Parkinson's up to Hoehn and Yahr stage 3, BMI 18.5 to 24.9, confirmed hypovitaminosis D (<30 ng/ml), who are on levodopa and not already taking vitamin D or other medications or having medical conditions that affect EEG or calcium metabolism, and active smokers are excluded.

## Eligibility

- **Minimum age:** 51 Years
- **Maximum age:** 70 Years
- **Sex:** MALE

### Full Criteria

```
Inclusion Criteria:

* Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale
* Age: 51years to70 years
* BMI: 18.5-24.9 kg/m2
* Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml)
* Patients on Levodopa therapy

Exclusion Criteria:

* Already taking vitamin D3 supplements
* Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.
* Patients who are currently suffering from following diseases

  * Neurological disorders (Migraine, epilepsy)
  * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)
  * Respiratory disorders (Bronchial asthma, COPD)
  * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)
* With biochemical evidence of-

  * Hypercalcemia
  * Renal insufficiency
  * Liver diseases
  * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)
* Active smoker
```

## Locations (1)

- Bangladesh medical university, Dhaka, Shahbag, Bangladesh _(23.7104, 90.4074)_
  - Jannatul Ferdoush Sumi, MBBS, MD Resident (phase B) — (CONTACT) — +8801875236686 — jannatsumi37@gmail.com
  - SUAYYA BINTE RAZZAQUE, MBBS,MD RESIDENT PHASE B — (CONTACT) — + 8801731660607

---

*Canonical: https://parkinsonspathways.com/trial/NCT07096336*  
*HTML version: https://parkinsonspathways.com/trial/NCT07096336*  
*Source data: https://clinicaltrials.gov/study/NCT07096336*